Printer Friendly

Atopic dermatitis pipeline promising.

PARIS -- An investigational anti-inflammatory drug shows promise in reducing the severity of mild to moderate atopic dermatitis, Dr. Karl Beutner said in a poster presentation at the annual meeting of the European Society for Dermatological Research.

A total of 103 patients with mild to moderate atopic dermatitis (body surface area 3%-10%) were randomized to twice-daily treatment with 1% AN0128 (67 patients)--AN0128 has been shown to block inflammatory cytokines in vitro--or the vehicle cream (36 patients) for 4 weeks, wrote Dr. Beutner, chief medical officer of Anacor Pharmaceuticals Inc. in Palo Alto, Calif.

Subjects were evaluated with the six-point Investigator's Static Global Assessment at baseline and on days 3, 7, 14, 28, and 35. With the ISGA, patients are rated as clear, almost clear, mild, moderate, severe, or very severe. Treatment success was defined as a rating of clear or almost dear. All other ratings were treatment failures.

At the end of 4 weeks, 51% of the AN0128 group reached a level of clear or almost clear, vs. 37% of controls.

COPYRIGHT 2006 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Skin Disorders
Author:Wachter, Jerri
Publication:Family Practice News
Article Type:Brief article
Geographic Code:4EUFR
Date:Nov 15, 2006
Previous Article:Atopic dermatitis tamed by repair of skin barrier.
Next Article:Early trauma tied to adult mental, physical health.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters